REG - Haleon PLC - Appointment of Vindi Banga as Chair

HALEONAnnouncement

10/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251110:nRSJ8412Ga&default-theme=true

RNS Number : 8412G  Haleon PLC  10 November 2025

 

 

Haleon plc: Appointment of Vindi Banga as Chair

 

10 November 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces the resignation of Sir Dave Lewis as Chair and appointment of Vindi
Banga.

 

Dave Lewis will step down as Chair of the Board and as a Director of the
Company on 31 December 2025 in order to pursue a new executive role. The Board
is pleased to announce the appointment of Vindi Banga as Chair to succeed Dave
with effect from 1 January 2026.

 

Vindi has served as Senior Independent Director on the Haleon Board since the
Company's listing in 2022. The Board was unanimous in its appointment of Vindi
given his wealth of global corporate and commercial leadership experience. He
has an extensive track record of delivering outstanding performance in highly
competitive global consumer-focused businesses and a deep understanding of
operating across developed and emerging markets. He spent 33 years at Unilever
plc, where he was also CEO and Chair of Hindustan Unilever Ltd, one of India's
largest listed companies, and was also responsible for Global Home &
Personal Care, Foods and Ice Cream and a member of the Unilever Executive
Board.

 

Vindi also has extensive international Board experience. He is currently Chair
of UK Government Investments Limited (UKGI) and has previously served as
Senior Independent Director at GSK and Marks and Spencer plc. Vindi is a
partner at CD&R, a leading private investment firm where he has chaired
and served on the boards of several of the firm's portfolio companies. He is
Chair of Council of Imperial College London.

Vindi's remuneration and the appointment of a successor as Senior Independent
Director will be announced in due course and before Vindi's appointment as
Chair takes effect.

 

Sir Dave Lewis commented: "After more than three years Haleon is now well
established as an independent listed company. The Board and Executive team are
strong and the business is performing well in a tough environment. The
leverage at demerger has been effectively addressed, the large overhang
managed smoothly and the portfolio reshaping is progressing.

 

My decision to step down is a personal one and is related to a new unique
opportunity which I wish to take forward. I would like to thank my Board
colleagues, Brian and his team for their support and commitment. It has been a
privilege to be part of Haleon and I am confident that the business has a
bright future."

 

Vindi Banga commented: "On behalf of the Board, I would like to thank Dave for
his leadership and the considerable contribution he has made as Chair of
Haleon since its listing in July 2022. It is a privilege to Chair Haleon and I
look forward to working with the Board and management team to support Haleon's
continued development."

 

The Company confirms that there is no further information to be disclosed
under the requirements of UKLR 6.4.6R.

 

Enquiries

 

 Investors                                    Media

 Jo Russell              +44 7787 392441      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Victoria Durman     +44 7894 505730

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans six major categories - Oral Health, Vitamins, Minerals and Supplements
(VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

About Vindi Banga

https://www.haleon.com/who-we-are/leadership#manvinder-singh-banga
(https://www.haleon.com/who-we-are/leadership#manvinder-singh-banga)

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOALKLLBEFLBFBL



            Copyright 2019 Regulatory News Service, all rights reserved